CY1109463T1 - Πεπτιδια kdr και εμβολια που τα περιλαμβανουν - Google Patents

Πεπτιδια kdr και εμβολια που τα περιλαμβανουν

Info

Publication number
CY1109463T1
CY1109463T1 CY20091100856T CY091100856T CY1109463T1 CY 1109463 T1 CY1109463 T1 CY 1109463T1 CY 20091100856 T CY20091100856 T CY 20091100856T CY 091100856 T CY091100856 T CY 091100856T CY 1109463 T1 CY1109463 T1 CY 1109463T1
Authority
CY
Cyprus
Prior art keywords
peptides
amino acid
kdr
shapes
vaccines including
Prior art date
Application number
CY20091100856T
Other languages
English (en)
Inventor
Hideaki Tahara
Satoshi Wada
Takuya Tsunoda
Original Assignee
Oncotherapy Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science, Inc. filed Critical Oncotherapy Science, Inc.
Publication of CY1109463T1 publication Critical patent/CY1109463T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464409—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Η παρούσα εφεύρεση παρέχει εννεαπεπτίδια επιλεγόμενα από πεπτίδια περιλαμβάνοντα την αλληλουχία αμινοξέων ΑΚΟΛ. ΑΡ. ΤΑΥΤ.: 2, 3, 5, 8, 11 ή 12• εννεαπεπτίδια ή δεκαπεπτίδια επιλεγόμενα από τα πεπτίδια που περιλαμβάνουν την αλληλουχία αμινοξέων ΑΚΟΛ. ΑΡ. ΤΑΥΤ.: 29, 30, 33, 34, 40 ή 46• και πεπτίδια με ικανότητα επαγωγής κυτταροτοξικών κυττάρων Τ στα οποία ένα, δύο ή περισσότερα αμινοξέα αντικαθίστανται ή προστίθενται στις προαναφερθείσες αλληλουχίες αμινοξέων, καθώς και φάρμακα για την αγωγή ή την πρόληψη όγκων, όπου τα φάρμακα περιλαμβάνουν αυτά τα πεπτίδια. Τα πεπτίδια της παρούσης εφευρέσεως μπορούν να χρησιμοποιηθούν ως εμβόλια.
CY20091100856T 2002-09-12 2009-08-12 Πεπτιδια kdr και εμβολια που τα περιλαμβανουν CY1109463T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002267285 2002-09-12
JP2003062003 2003-03-07
JP2003167042 2003-06-11
EP03795432A EP1548032B9 (en) 2002-09-12 2003-09-12 Kdr peptides and vaccines comprising the same

Publications (1)

Publication Number Publication Date
CY1109463T1 true CY1109463T1 (el) 2014-08-13

Family

ID=31998762

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100856T CY1109463T1 (el) 2002-09-12 2009-08-12 Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
CY20121100072T CY1113379T1 (el) 2002-09-12 2012-01-19 Πεπτιδια κdr και εμβολια που τα περιλαμβανουν

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100072T CY1113379T1 (el) 2002-09-12 2012-01-19 Πεπτιδια κdr και εμβολια που τα περιλαμβανουν

Country Status (14)

Country Link
US (5) US7514084B2 (el)
EP (11) EP2014678B1 (el)
JP (3) JP3971769B2 (el)
CN (5) CN100352843C (el)
AT (2) ATE432291T1 (el)
AU (1) AU2003264419A1 (el)
CY (2) CY1109463T1 (el)
DE (1) DE60327786D1 (el)
DK (6) DK2267022T3 (el)
ES (2) ES2375299T3 (el)
HK (7) HK1124077A1 (el)
PT (2) PT2014678E (el)
SI (2) SI2014678T1 (el)
WO (1) WO2004024766A1 (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100352843C (zh) 2002-09-12 2007-12-05 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
JP4628208B2 (ja) * 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
PL2325305T3 (pl) * 2005-02-25 2014-07-31 Oncotherapy Science Inc Szczepionki peptydowe na nowotwory płuc z ekspresją polipeptydów TTK, URLC10 lub KOC1
SI2289533T1 (sl) * 2005-02-28 2013-11-29 Oncotherapy Science, Inc. Epitopni peptidi, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja in cepiva, ki vsebujejo te peptide
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
US7943295B2 (en) 2005-07-29 2011-05-17 Oncotherapy Science, Inc. Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex
PL2347775T3 (pl) 2005-12-13 2020-11-16 President And Fellows Of Harvard College Rusztowania do przeszczepiania komórek
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗
ES2405763T3 (es) 2007-02-16 2013-06-03 Oncotherapy Science, Inc. Vacunoterapia para la neovascularización coroidea
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
EP2189471B1 (en) 2007-08-20 2017-10-04 Oncotherapy Science, Inc. Foxm1 peptide and medicinal agent comprising the same
JP5493076B2 (ja) * 2007-08-20 2014-05-14 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１ペプチド及びこれを含む薬剤
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
TW200932260A (en) * 2007-11-28 2009-08-01 Oncotherapy Science Inc STAT3 epitope peptides
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
AU2009214038B2 (en) 2008-02-14 2013-08-22 Katholieke Universiteit Leuven Elimination of immune responses to viral vectors
WO2009101208A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunotherapy targeting intracellular pathogens
CA2715488C (en) 2008-02-14 2019-09-24 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
ES2650236T3 (es) 2008-02-14 2018-01-17 Life Sciences Research Partners Vzw Linfocitos T CD4+ con propiedades citolíticas
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
CA2737040C (en) 2008-09-19 2017-05-02 Nektar Therapeutics Polymer conjugates of therapeutic peptides
RU2532105C2 (ru) 2008-10-22 2014-10-27 Онкотерапи Сайенс, Инк. Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
TWI539160B (zh) * 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
TW201032820A (en) * 2008-12-16 2010-09-16 Oncotherapy Science Inc ELOVL7 epitope peptides and vaccines containing the same
BRPI0923402A2 (pt) * 2008-12-24 2015-08-04 Oncotherapy Science Inc Peptídeos c10rf59 e vacinas incluindo os mesmos.
CN103690928B (zh) 2009-01-08 2016-04-20 株式会社癌免疫研究所 新型癌抗原eEF2
CN102439147A (zh) * 2009-03-04 2012-05-02 肿瘤疗法科学股份有限公司 Vangl1肽及包含它们的疫苗
PT2408913T (pt) * 2009-03-18 2017-03-07 Oncotherapy Science Inc Péptidos neil3 e vacinas que incluem os mesmos
TW201100090A (en) * 2009-04-01 2011-01-01 Oncotherapy Science Inc C6orf167 peptides and vaccines containing the same
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
AU2010278702C1 (en) * 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
TW201200525A (en) * 2009-12-04 2012-01-01 Oncotherapy Science Inc MYBL2 peptides and vaccines containing the same
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
CN102115492B (zh) * 2010-01-05 2013-03-06 中国农业科学院北京畜牧兽医研究所 血管内皮生长因子受体部分多肽及其应用
SG10201501857YA (en) * 2010-03-11 2015-05-28 Oncotherapy Science Inc Hjurp Peptides And Vaccines Including The Same
TW201134480A (en) * 2010-04-08 2011-10-16 Oncotherapy Science Inc CLUAP1 peptides and vaccines including the same
SG183945A1 (en) * 2010-04-09 2012-10-30 Oncotherapy Science Inc Cdca5 peptides and vaccines including the same
WO2012032763A1 (en) * 2010-09-07 2012-03-15 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
CA2813751C (en) 2010-10-06 2019-11-12 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
RU2615460C2 (ru) 2010-11-25 2017-04-04 Имнейт Сарл Иммуногенные пептиды для применения в профилактике и/или лечении инфекционных заболеваний, аутоиммунных заболеваний, иммунных ответов на аллогенные факторы, аллергических заболеваний, опухолей, отторжения трансплантата и иммунных ответов против вирусных векторов. используемых для генной терапии или генной вакцинации
MY166516A (en) * 2010-12-02 2018-07-05 Oncotherapy Science Inc Tomm34 peptides and vaccines including the same
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
CN104168917A (zh) 2012-03-09 2014-11-26 肿瘤疗法科学股份有限公司 含有肽的医药组合物
CA2870309C (en) 2012-04-16 2024-02-20 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
CN104470950B (zh) 2012-05-11 2017-04-26 公益财团法人微生物化学研究会 抗cxadr抗体
EP2872532A4 (en) 2012-07-10 2016-04-13 Oncotherapy Science Inc CDCA1-EPITOPPEPTIDES FOR TH1 CELLS AND VACCINES THEREWITH
WO2014087626A1 (en) * 2012-12-04 2014-06-12 Oncotherapy Science, Inc. Sema5b peptides and vaccines containing the same
US9932396B2 (en) 2013-02-08 2018-04-03 Medical & Biological Laboratories Co., Ltd. Antibody against human NRG1 protein
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
JP2017042047A (ja) * 2013-12-06 2017-03-02 オンコセラピー・サイエンス株式会社 Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
WO2015168379A2 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016129335A1 (ja) * 2015-02-09 2016-08-18 株式会社ライフアートビレッジ 免疫細胞療法のためのペプチドスクリーニング方法
CN107708756A (zh) 2015-04-10 2018-02-16 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
JP7090335B2 (ja) 2015-09-25 2022-06-24 イムサイス エスエー 治療剤に対する免疫応答を除去するための改善された方法及び化合物
CN105200010B (zh) * 2015-10-15 2019-02-12 首都医科大学附属北京佑安医院 艾滋病感染者hla-a2特异性ctl细胞的体外培养方法及其专用培养基
EP3411475A4 (en) 2016-02-06 2019-09-11 President and Fellows of Harvard College REGENERATION OF THE HEMATOPOIETIC NICHE TO RECONSTITUTE IMMUNITY
SG11201808710UA (en) 2016-04-19 2018-11-29 Imcyse Sa Novel immunogenic cd1d binding peptides
CN115305229A (zh) 2016-07-13 2022-11-08 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
CN110612115A (zh) * 2017-05-19 2019-12-24 学校法人庆应义塾 针对脑神经疾病的肽疫苗和肽疫苗组合物
CN111363026B (zh) * 2020-03-31 2022-03-25 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 一种增强抗原多肽亲和力和稳定性的方法
KR20220022021A (ko) * 2020-08-14 2022-02-23 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
CN1173991C (zh) * 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
CA2158745C (en) 1993-03-25 2007-06-19 Richard L. Kendall Inhibitor of vascular endothelial cell growth factor
DE69635895D1 (de) * 1995-08-03 2006-05-04 Rijksuniversiteit Te Leiden Le Antigen presentierende bläschen, die von zellen ableiten
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
US5942428A (en) * 1996-08-21 1999-08-24 Sugen, Inc. Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998031794A1 (fr) * 1997-01-17 1998-07-23 Toa Gosei Co., Ltd. Polypeptide liant le facteur vegf
ATE371727T1 (de) * 1997-06-18 2007-09-15 Merck & Co Inc Kdr, ein menschlicher tyrosin kinase rezeptor
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
CN1284083A (zh) * 1997-12-05 2001-02-14 伊东恭悟 肿瘤抗原肽衍生物
AU2299099A (en) * 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
GB9804121D0 (en) * 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
CA2328893A1 (en) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
KR100653590B1 (ko) 1998-06-25 2006-12-04 교고 이또 시클로필린 ｂ 유래의 종양 항원 펩티드
AU6600400A (en) * 1999-08-13 2001-03-13 Crucell Holland B.V. Methods and means for inhibiting angiogenesis
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
JP2002267285A (ja) 2001-03-12 2002-09-18 Denso Corp 冷房冷蔵装置
JP4068371B2 (ja) 2001-06-13 2008-03-26 株式会社トプコン 手術用顕微鏡
JP3640084B2 (ja) 2001-11-30 2005-04-20 日本電気株式会社 測位機能を搭載した携帯電話端末
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
CN100352843C (zh) * 2002-09-12 2007-12-05 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
JP2006511475A (ja) 2002-09-18 2006-04-06 トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 脈絡膜新生血管症の抑制方法
SI2289533T1 (sl) * 2005-02-28 2013-11-29 Oncotherapy Science, Inc. Epitopni peptidi, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja in cepiva, ki vsebujejo te peptide
ES2405763T3 (es) 2007-02-16 2013-06-03 Oncotherapy Science, Inc. Vacunoterapia para la neovascularización coroidea
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌

Also Published As

Publication number Publication date
EP1548032B9 (en) 2009-10-28
EP2267022A2 (en) 2010-12-29
EP2267023A3 (en) 2011-02-16
SI1548032T1 (sl) 2009-10-31
US20100215676A1 (en) 2010-08-26
US20130028923A1 (en) 2013-01-31
ATE531729T1 (de) 2011-11-15
EP2014678A3 (en) 2009-03-25
CN1694901A (zh) 2005-11-09
EP2270042B1 (en) 2015-01-14
HK1151039A1 (en) 2012-01-20
JPWO2004024766A1 (ja) 2006-01-26
AU2003264419A1 (en) 2004-04-30
EP2270041A3 (en) 2011-02-16
DK2261249T3 (en) 2015-02-16
HK1124077A1 (en) 2009-07-03
JP2007191485A (ja) 2007-08-02
HK1151038A1 (en) 2012-01-20
EP2270041A2 (en) 2011-01-05
EP2014678A2 (en) 2009-01-14
EP2267023B1 (en) 2015-02-11
EP2267021B1 (en) 2015-02-18
EP2261248B1 (en) 2015-02-18
US7695720B2 (en) 2010-04-13
EP2267023A2 (en) 2010-12-29
US20090252752A1 (en) 2009-10-08
CN103073620A (zh) 2013-05-01
EP1548032B1 (en) 2009-05-27
EP2014678B1 (en) 2011-11-02
CN101139392A (zh) 2008-03-12
CN100352843C (zh) 2007-12-05
CN101139392B (zh) 2012-12-26
DK2267021T3 (en) 2015-03-30
JP2007277251A (ja) 2007-10-25
CN103951745A (zh) 2014-07-30
EP2261249A2 (en) 2010-12-15
EP2014679B1 (en) 2010-05-05
US20060216301A1 (en) 2006-09-28
ES2327040T3 (es) 2009-10-23
EP2261248A2 (en) 2010-12-15
EP2261247A2 (en) 2010-12-15
WO2004024766A1 (ja) 2004-03-25
EP2270042A2 (en) 2011-01-05
US8206719B2 (en) 2012-06-26
JP4185143B2 (ja) 2008-11-26
EP2267021A2 (en) 2010-12-29
EP2261247A3 (en) 2011-02-16
EP2014679A1 (en) 2009-01-14
EP2267022A3 (en) 2011-02-16
DK2014678T3 (da) 2012-02-06
HK1151036A1 (en) 2012-01-20
DK2267023T3 (en) 2015-02-23
DE60327786D1 (de) 2009-07-09
EP2261249B1 (en) 2015-02-11
CN103073620B (zh) 2014-12-10
SI2014678T1 (sl) 2012-03-30
EP2261249A3 (en) 2011-02-16
US7514084B2 (en) 2009-04-07
PT1548032E (pt) 2009-08-13
JP3971769B2 (ja) 2007-09-05
HK1151037A1 (en) 2012-01-20
ATE432291T1 (de) 2009-06-15
DK1548032T3 (da) 2009-08-17
CY1113379T1 (el) 2016-06-22
HK1151032A1 (en) 2012-01-20
JP4185147B2 (ja) 2008-11-26
EP2267022B1 (en) 2015-02-11
EP2270042A3 (en) 2011-02-16
US8574585B2 (en) 2013-11-05
PT2014678E (pt) 2012-01-05
ES2375299T3 (es) 2012-02-28
CN101139393A (zh) 2008-03-12
EP2261248A3 (en) 2011-02-16
US20120328636A1 (en) 2012-12-27
DK2267022T3 (en) 2015-02-23
EP1548032A4 (en) 2006-03-01
EP2270041B1 (en) 2015-02-25
HK1125659A1 (en) 2009-08-14
EP2267021A3 (en) 2011-02-16
EP1548032A1 (en) 2005-06-29
CN101139393B (zh) 2010-11-24
US8574586B2 (en) 2013-11-05

Similar Documents

Publication Publication Date Title
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
PT2121731E (pt) Vacinas peptídicas para cancros que expressam antigénios associados a tumores
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
BG106008A (en) Novel lhrh antagonists with improved solubility characteristics
DK1352056T3 (da) Polypeptider, der er i stand til at fremkalde en immunreaktion mod cancer
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
EP2370454A4 (en) PEPTIDES WITH EPITAOPE WDRPUH AND VACCINES INCLUDING THEM
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
DE50205579D1 (de) Semi-allogene antitumor-vakzine mit hla-haplo-identischen antigen-präsentierenden zellen
CY1114720T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
CY1117399T1 (el) Συνθεσεις και μεθοδοι για προληψη και θεραπεια νευροεκφυλιστικων ασθενειων
PT1537210E (pt) Inibicao de oliconucleotidos decoy de expressao cd-40
CY1109617T1 (el) Ενα πεπτιδιο hsp70 που διεγειρει τη δραστηριοτητα φυσικων φονικων κυτταρων (νκ) και χρησεις αυτου